Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw unusually-high trading volume on Friday . 5,255 shares were traded during mid-day trading, an increase of 88% from the previous session’s volume of 2,795 shares.The stock last traded at $50.51 and had previously closed at $50.00.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZLDPF. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Zacks Research downgraded Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Up 1.0%

The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of 8.38 and a beta of 0.88. The firm has a 50 day moving average price of $46.38 and a two-hundred day moving average price of $48.86.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.